Pages that link to "Q28390399"
Jump to navigation
Jump to search
The following pages link to Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients (Q28390399):
Displaying 29 items.
- In vitro cancer cell-ECM interactions inform in vivo cancer treatment (Q26781263) (← links)
- Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway (Q26797238) (← links)
- Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity (Q28075996) (← links)
- Current issues in malignant pleural mesothelioma evaluation and management (Q28393560) (← links)
- Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies (Q28395597) (← links)
- Antibody-based immunotherapy for malignant glioma (Q34120472) (← links)
- Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms. (Q35840270) (← links)
- KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. (Q36035319) (← links)
- Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients (Q36040200) (← links)
- Old medications and new targeted therapies in systemic sclerosis (Q36154430) (← links)
- Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity (Q38203261) (← links)
- Immune therapies for malignant mesothelioma (Q38212149) (← links)
- Overcoming tumor-mediated immunosuppression (Q38262255) (← links)
- Searching for targets for the systemic therapy of mesothelioma. (Q38365768) (← links)
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy (Q38416306) (← links)
- Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics. (Q38563910) (← links)
- Autophagy: controlling cell fate in rheumatic diseases (Q38873681) (← links)
- The predictive value of transforming growth factor-β in Wilms tumor immunopathogenesis (Q39290714) (← links)
- Transforming growth factor-β: A therapeutic target for cancer (Q39346505) (← links)
- Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. (Q39415827) (← links)
- Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease (Q39595554) (← links)
- Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactions (Q42551215) (← links)
- Targeted Therapies Against Growth Factor Signaling in Breast Cancer (Q47559665) (← links)
- Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection (Q50041876) (← links)
- Immunotherapy advances for mesothelioma treatment. (Q51823843) (← links)
- Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV (Q90468887) (← links)
- Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling (Q90643368) (← links)
- TGFβ biology in cancer progression and immunotherapy (Q97867213) (← links)
- Targeting TGFβ signal transduction for cancer therapy (Q104795035) (← links)